/ASMB
ASMB Stock - Assembly Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$35.26+9.00%
+$2.91 (+9.00%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.93
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).71
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.74
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.6%upside
Target: $39.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ASMB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$34.91 – $35.61
TARGET (TP)$39.00
STOP LOSS$32.44
RISK/REWARD1:1.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.15
52W High$39.71
52W Low$7.75
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $28.52M | $7.16M | N/A | $6.25M | $79.11M |
| Gross Profit | $28.52M | $-41,737,000 | $-69,080,000 | $6.25M | $-22,232,000 |
| Gross Margin | 100.0% | -582.7% | N/A | 100.0% | -28.1% |
| Operating Income | $-45,420,000 | $-64,646,000 | $-94,114,000 | $-132,688,000 | $-64,775,999 |
| Net Income | $-40,177,000 | $-61,228,000 | $-93,092,000 | $-129,855,000 | $-62,152,000 |
| Net Margin | -140.9% | -854.8% | N/A | -2076.4% | -78.6% |
| EPS | $-6.69 | $-13.38 | $-22.82 | $-36.00 | $-15.00 |
Company Overview
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$39
Average Target
↑ 9.2% Upside
Now
$31
Low
$39
Average
$50
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 24th 2025 | Citizens JMP | Initiation | Mkt Outperform | $38 |
| August 18th 2025 | H.C. Wainwright | Resumed | Buy | $50 |
| March 25th 2025 | Guggenheim | Initiation | Buy | $31 |
| September 20th 2024 | Jefferies | Upgrade | Buy | $35← $2 |
Earnings History & Surprises
ASMBBeat Rate
61%
Last 18 quarters
Avg Surprise
+3.9%
EPS vs Estimate
Beats / Misses
11/6
1 met exactly
Latest EPS
$-0.72
Q4 2025
EPS Surprise History
Q1 24
+25.3%
$-2.15vs$-2.88
Q2 24
+39.4%
$-1.66vs$-2.74
Q3 24
+33.1%
$-1.98vs$-2.96
Q4 24
+25.2%
$-1.51vs$-2.02
Q1 25
+10.3%
$-1.57vs$-1.75
Q2 25
+41.8%
$-1.17vs$-2.01
Q3 25
-103.6%
$-1.33vs$-0.65
Q4 25
-44.0%
$-0.72vs$-0.50
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.51 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.50 | $-0.72 | -44.0% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.65 | $-1.33 | -103.6% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-2.01 | $-1.17 | +41.8% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-1.75 | $-1.57 | +10.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-2.02 | $-1.51 | +25.2% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-2.96 | $-1.98 | +33.1% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-2.74 | $-1.66 | +39.4% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-2.88 | $-2.15 | +25.3% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-2.76 | $-3.24 | -17.4% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-3.48 | $-3.84 | -10.3% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-4.44 | $-4.44 | 0.0% | = MET |
Q1 2023 | Mar 22, 2023 | $-6.72 | $-5.52 | +17.9% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-5.64 | $-5.76 | -2.1% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-5.88 | $-6.12 | -4.1% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-5.88 | $-5.76 | +2.0% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-6.00 | $-4.92 | +18.0% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-6.60 | $-4.92 | +25.5% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-7.68 | $-6.60 | +14.1% | ✓ BEAT |
Latest News
Assembly Biosciences Reports Interim Results From Phase 1b Studies Showing 98% Reduction In HSV-2 Shedding Rate With ABI-1179; ABI-5366 Monthly Dose cohort Showed 76% Reduction In HSV-2 Shedding rate
📈 PositiveBenzinga•Dec 8, 2025, 09:07 PM
Mizuho Maintains Outperform on Assembly Biosciences, Raises Price Target to $40
📈 PositiveBenzinga•Nov 20, 2025, 04:31 PM
Assembly Biosciences Q3 EPS $(0.72) Beats $(0.78) Estimate, Sales $10.789M Beat $7.459M Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:41 PM
Assembly Biosciences Data From Phase 1b Study Demonstrates ABI-4334 Was Well Tolerated Across Both Dose Levels In Patients With Chronic Hepatitis B
📈 PositiveBenzinga•Nov 7, 2025, 01:09 PM
Assembly Biosciences Files Prospectus Relates To Offering, Resale From Time To Time Of Up To 6.98M Shares By Selling Stockholder
➖ NeutralBenzinga•Oct 14, 2025, 08:24 PM
HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target
📈 PositiveBenzinga•Oct 14, 2025, 11:17 AM
Assembly Biosciences Highlights Interim Phase 1b Clinical Data For Long-Acting HSV Helicase-Primase Inhibitor Candidate ABI-5366 In Late-Breaking Oral Presentation At Congress Of IUSTI- Europe
📈 PositiveBenzinga•Oct 10, 2025, 12:09 PM
JMP Securities Initiates Coverage On Assembly Biosciences with Market Outperform Rating, Announces Price Target of $38
📈 PositiveBenzinga•Sep 24, 2025, 01:00 PM
Guggenheim Maintains Buy on Assembly Biosciences, Raises Price Target to $39
📈 PositiveBenzinga•Sep 8, 2025, 01:38 PM
HC Wainwright & Co. Assumes Assembly Biosciences at Buy, Announces Price Target of $50
📈 PositiveBenzinga•Aug 18, 2025, 10:40 AM
Frequently Asked Questions about ASMB
What is ASMB's current stock price?
Assembly Biosciences, Inc. (ASMB) is currently trading at $35.26 per share. The stock has moved +9.00% today.
What is the analyst price target for ASMB?
The average analyst price target for ASMB is $39.00, based on 1 analyst.
What sector is Assembly Biosciences, Inc. in?
Assembly Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ASMB's market cap?
Assembly Biosciences, Inc. has a market capitalization of $0.30 billion, making it a small-cap company.
Does ASMB pay dividends?
No, Assembly Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAARD
Aardvark Therapeutics, Inc. Common Stock
$13.77
Mkt Cap: $0.3B
ARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
IMRX
Immuneering Corporation
$5.65
Mkt Cap: $0.2B
NAUT
Nautilus Biotechnology, Inc.
$1.94
Mkt Cap: $0.2B
PYXS
Pyxis Oncology, Inc.
$1.27
Mkt Cap: $0.1B
SGMT
Sagimet Biosciences Inc.
$6.28
Mkt Cap: $0.2B
TNYA
Tenaya Therapeutics, Inc.
$0.70
Mkt Cap: $0.1B
ZURA
Zura Bio Limited
$4.27
Mkt Cap: $0.3B
Explore stocks similar to ASMB for comparison